Research programme: bispecific antibody therapeutics - Pandion Therapeutics

Drug Profile

Research programme: bispecific antibody therapeutics - Pandion Therapeutics

Latest Information Update: 22 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pandion Therapeutics
  • Class Anti-inflammatories; Antihyperglycaemics; Bispecific antibodies; Hepatoprotectants; Immunotherapies; Skin disorder therapies; Urologics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Inflammatory bowel diseases; Kidney disorders; Liver disorders; Skin disorders; Type 1 diabetes mellitus

Most Recent Events

  • 18 Jan 2018 Research programme: bispecific antibody therapeutics - Pandion Therapeutics is available for licensing as of 18 Jan 2018. www.pandiontx.com
  • 18 Jan 2018 Pandion Therapeutics has patents pending for its bispecific antibody technology platform and applications
  • 18 Jan 2018 Early research in Inflammatory bowel disease in USA (Parenteral) before January 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top